Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1b Study of PF-04449913 (Glasdegib) in Combination With Azacitidine in Patients With Previously Untreated Higher-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

NCT02367456 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02367456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02367456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1b Study of PF-04449913 (Glasdegib) in Combination With Azacitidine in Patients With Previously Untreated Higher-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
April 28, 2015
Completion date
March 7, 2022
Enrollment
73 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome